A detailed history of Capital Impact Advisors, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Capital Impact Advisors, LLC holds 26,554 shares of NTLA stock, worth $380,518. This represents 1.7% of its overall portfolio holdings.

Number of Shares
26,554
Previous 31,993 17.0%
Holding current value
$380,518
Previous $880,000 32.5%
% of portfolio
1.7%
Previous 1.17%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 16, 2024

SELL
$20.02 - $27.22 $108,888 - $148,049
-5,439 Reduced 17.0%
26,554 $594,000
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $139,704 - $192,371
5,865 Added 22.45%
31,993 $880,000
Q4 2023

Feb 14, 2024

BUY
$23.16 - $32.34 $341,610 - $477,015
14,750 Added 129.64%
26,128 $796,000
Q2 2023

Aug 14, 2023

BUY
$34.58 - $46.03 $23,272 - $30,978
673 Added 6.29%
11,378 $463,000
Q4 2022

Feb 14, 2023

SELL
$33.21 - $62.69 $41,479 - $78,299
-1,249 Reduced 10.45%
10,705 $373,000
Q3 2022

Nov 21, 2022

BUY
$53.92 - $71.7 $25,018 - $33,268
464 Added 4.04%
11,954 $586,000
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $126,632 - $250,730
3,290 Added 40.12%
11,490 $595,000
Q1 2022

May 16, 2022

BUY
$58.27 - $118.99 $194,505 - $397,188
3,338 Added 68.65%
8,200 $596,000
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $265,804 - $364,993
-2,638 Reduced 35.17%
4,862 $575,000
Q3 2021

Nov 15, 2021

BUY
$132.37 - $176.78 $992,775 - $1.33 Million
7,500 New
7,500 $1.01 Million
Q2 2021

Aug 17, 2021

SELL
$60.88 - $161.91 $272,011 - $723,413
-4,468 Closed
0 $0
Q1 2021

May 18, 2021

SELL
$46.59 - $83.68 $10 Million - $18 Million
-215,532 Reduced 97.97%
4,468 $359,000
Q4 2020

Feb 12, 2021

BUY
$18.83 - $63.53 $2.07 Million - $6.99 Million
110,000 Added 100.0%
220,000 $12 Million
Q3 2020

Nov 13, 2020

BUY
$17.47 - $24.93 $1.92 Million - $2.74 Million
110,000 New
110,000 $2.19 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.09B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Capital Impact Advisors, LLC Portfolio

Follow Capital Impact Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capital Impact Advisors, LLC with notifications on news.